Funds for R&D in drug discovery and manufacturing :PIB
An outlay of Rs. 1,500 crore has been approved for strengthening/ up-gradation of these NIPERs for the period 2021-22 to 2025-26.
An outlay of Rs. 1,500 crore has been approved for strengthening/ up-gradation of these NIPERs for the period 2021-22 to 2025-26.
The tenure of contract will be upto 10 years from date of signing the contract/installation.
WuXi STA opens a new large scale continuous manufacturing plant
Better serving global partners and advancing healthcare innovation
The company now exceeds the sector benchmark for its overall ESG rating and for all three measures
PM congratulates citizens on crossing the 200 crore milestone of Covid vaccination drive
Manish led SeQuent since 2014 and played a major role in transforming the company
To strengthen the integrated human-centric preventive health screening ‘Phygital’ ecosystem in India
The round was closed with an investment from the European Circular Bioeconomy Fund (ECBF) and the two existing investors, Sofinnova Partners and Novo Seeds
Subscribe To Our Newsletter & Stay Updated